Aurinia Pharmaceuticals (AUPH) Short-term Investments (2017 - 2026)

Aurinia Pharmaceuticals has reported Short-term Investments for 9 years, with the latest figure at $337.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 37.04% year-over-year to $337.8 million; the trailing twelve-month figure through Mar 2026 stood at $337.8 million (up 37.04% YoY), and the FY2025 full-year result was $317.8 million, up 15.54% from the prior year.
• Short-term Investments for Q1 2026 stood at $337.8 million, up from $317.8 million in the prior quarter.
• The five-year high for Short-term Investments was $337.8 million in Q1 2026, with the low at $240.1 million in Q2 2022.
• Historically, Short-term Investments has averaged $284.0 million across 5 years, with a median of $286.2 million in 2022.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 49.3% — and 2025, when it fell 11.76%.
• Aurinia Pharmaceuticals' Short-term Investments stood at $295.2 million in 2022, then rose by 2.17% to $301.6 million in 2023, then declined by 8.81% to $275.0 million in 2024, then increased by 15.54% to $317.8 million in 2025, then increased by 6.29% to $337.8 million in 2026.
• The last three Short-term Investments figures came in at $337.8 million (Q1 2026), $317.8 million (Q4 2025), and $278.6 million (Q3 2025), per Business Quant data.